Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT07621757
NCT07621757Enrolling By InvitationNot Applicable

Prospective Trial for the Implementation of Genetic Risk for Colorectal Cancer Screening

Endeavor Health1 site in 1 country100 target enrollmentStarted: June 1, 2026Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Enrolling By Invitation
Sponsor
Enrollment
100
Locations
1
Study OverviewStudy DesignEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The goal of this study is to investigate genetic risk for colorectal cancer utilizing polygenic risk scores (PRS) for adults over 45 who have not received their first colonoscopy. The main questions it hopes to address are:

  1. How does knowledge of a patient's genetic risk for colorectal cancer affect the uptake of initial screening colonoscopies?
  2. How do colonoscopy outcomes compare between genetic risk groups?

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
45 Years to 75 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •- Due for initial screening colonoscopy per current guidelines

Exclusion Criteria

  • •Prior colonoscopy
  • •Prior personal history of colorectal cancer or inflammatory bowel disease
  • •Medical contraindications to colonoscopy/sedation

Investigators

Sponsor
Endeavor Health
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Jianfeng Xu

Vice President and Director, Genomic Translational Research

Endeavor Health

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Not Applicable
High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
NCT07463287Shanghai East Hospital100
Active, not recruiting
Phase 3
A study to evaluate the efficacy, safety and immunogenicity of Bevacizumab in metastatic colorectal cancer patients.
CTRI/2024/04/066032CuraTeQ Biologics Private Ltd168
Not yet recruiting
Not Applicable
Colorectal Adenoma CohortColorectal Neoplasms
NCT07523035Second Affiliated Hospital, School of Medicine, Zhejiang University1,280
Recruiting
Not Applicable
Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study
NCT07479381Harbinger Health1,450
Recruiting
Not Applicable
The Use of Artificial Intelligence for the Prediction of Recurrence After Resection of Colorectal Liver Metastases
NCT07385521Francesco De Cobelli1,000